2024-03-08 07:00:00 ET
Summary
- Avid Bioservices' stock plummeted 30% post-earnings; Q3 revenue fell 11%, with significant drops in gross margin and operating income.
- Announced planned $160 million 7.00% Convertible Senior Notes; default on 2026 Notes triggers cross-default, complicating finances.
- The current ratio was 1.35 in October, showing adequate short-term liquidity; however, $146 million in immediate debt repayment looms large.
- Downgrade to "Strong Sell" due to financial instability, eroding trust, and competitive market pressures, despite potential CDMO market growth.
From Caution to Strong Sell: Avid's Rocky Financial Waters
In August, I recommended a "hold" on Avid Bioservices ( CDMO ), a contract development and manufacturing organization, advocating for a "cautious approach due to near-term uncertainties and valuation concerns." The caution has played out, and its stock is off 50% while the S&P 500 is up a healthy 14.8% in the same period....
Read the full article on Seeking Alpha
For further details see:
Avid Bioservices Faces Financial Strain Amid Market Challenges (Rating Downgrade)